Compare ARQT & UTF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARQT | UTF |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.0B |
| IPO Year | 2020 | 2004 |
| Metric | ARQT | UTF |
|---|---|---|
| Price | $23.69 | $27.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $34.00 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 286.1K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $376,072,000.00 | N/A |
| Revenue This Year | $34.85 | N/A |
| Revenue Next Year | $29.39 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 91.34 | N/A |
| 52 Week Low | $12.72 | $23.42 |
| 52 Week High | $31.77 | $27.35 |
| Indicator | ARQT | UTF |
|---|---|---|
| Relative Strength Index (RSI) | 62.23 | 55.57 |
| Support Level | $22.41 | $26.54 |
| Resistance Level | $23.87 | $27.34 |
| Average True Range (ATR) | 0.85 | 0.27 |
| MACD | 0.34 | -0.01 |
| Stochastic Oscillator | 91.83 | 65.78 |
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. Under normal market conditions, the fund invests the majority of its managed assets in securities issued by infrastructure companies, which consist of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies.